Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicaid Expansion: Glass Half Full for Biopharma

This article was originally published in RPM Report

Executive Summary

Most health reform watchers have been tracking state votes on Medicaid expansion as a sort of scorecard on whether Obama Administration is winning or losing in health care reform. Push back from the states is making news now, but for biopharma sponsors, even a glass half full is a positive—and the long-term outlook is even brighter.


Related Content

Drug Spending Expected To Rise By $200 Bil. In 2022 Compared To Pre-ACA Levels
Medicaid Expansion: Can Texas Be Turned?
Managing ACA Expectations
Assessing The Sales Impact Of The New Health Insurance Exchange Market
Why ACA Is A Boon For Health Care, Hospitals: An Interview With Tom Scully
Deals Of The Week Ponders The ACA
Wall Street’s Take On Health Care Exchanges
Health Reform in 2013: The Sprint to the Starting Line
Betting and Winning: SCOTUS Decision Underscores High Stakes In Pharma’s Strategy
A Quick Metric for Measuring Pharma's Success in Healthcare Reform





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts